For the quarter ending 2026-02-28, CYDY has $18,497K in assets. $122,784K in debts. $15,655K in cash and cash equivalents.
| Balance Sheets | 2026-02-28 | 2025-11-30 | 2025-08-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 15,655 | 4,982 | 9,332 | |
| Prepaid expenses | 448 | 560 | 560 | |
| Prepaid service fees | 2,335 | 3,297 | 3,458 | |
| Total current assets | 18,438 | 8,839 | 13,350 | |
| Other non-current assets | 59 | 96 | 133 | |
| Total assets | 18,497 | 8,935 | 13,483 | |
| Convertible notes payable, net | - | 27,200 | 27,200 | |
| Accounts payable | 13,478 | 14,245 | 14,175 | |
| Accrued liabilities and compensation | 15,825 | 19,685 | 2,823 | |
| Accrued interest on convertible notes | 11,750 | 14,971 | 16,577 | |
| Accrued dividends on convertible preferred stock-Series CPreferred Stock | - | 4,087 | 3,929 | |
| Accrued dividends on convertible preferred stock-Series DPreferred Stock | - | 4,924 | 4,713 | |
| Accrued dividends on convertible preferred stock | 9,375 | - | - | |
| Total current liabilities | 50,428 | 85,112 | 69,417 | |
| Convertible notes payable, net | 27,200 | - | - | |
| Accrued interest on convertible notes | 1,585 | - | - | |
| Other liabilities (note 10) | 43,571 | 43,571 | 43,571 | |
| Total liabilities | 122,784 | 128,683 | 112,988 | |
| Preferred stock-Series BPreferred Stock | - | 0 | 0 | |
| Preferred stock-Series CPreferred Stock | - | 0 | 0 | |
| Preferred stock-Series DPreferred Stock | - | 0 | 0 | |
| Common stock, 0.001 par value 2,250,000 shares authorized 1,358,242 and 1,249,460 issued, and 1,357,956 and 1,249,174 outstanding at february 28, 2026 and may 31, 2025, respectively | 1,358 | 1,266 | 1,257 | |
| Additional paid-in capital | 814,978 | 794,919 | 792,564 | |
| Accumulated deficit | -920,623 | -915,933 | -893,326 | |
| Total stockholders' deficit | -104,287 | -119,748 | -99,505 | |
| Total liabilities and stockholders' deficit | 18,497 | 8,935 | 13,483 | |
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)